# Neumora Therapeutics, Inc.: overview NMRA · Nasdaq · CIK 1885522 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nmra.md) · [Financials](/companies/nmra/financials.md) · [Filings](/companies/nmra/filings.md) · [Insiders](/companies/nmra/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.45)](/filings/0001193125-25-269446.md) | not reported | [(0.42)](/filings/0001193125-26-211825.md) | [(0.33)](/filings/0001193125-26-350370.md) | [(0.35)](/filings/0001193125-25-269446.md) | not reported | [(0.30)](/filings/0001193125-26-211825.md) | [(0.23)](/filings/0001193125-26-350370.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(4.81)](/filings/0000950170-25-030401.md) | [(3.63)](/filings/0000950170-25-030401.md) | [(1.53)](/filings/0001193125-26-130388.md) | [(1.45)](/filings/0001193125-26-130388.md) | | Free cash flow | $m | [(115)](/filings/0000950170-25-030401.md) | [(163)](/filings/0000950170-25-030401.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nmra/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $14.4m | 8,497,822 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $13.2m | 7,791,869 | | Added +5,737,553 | | [SOFTBANK GROUP CORP.](/funds/1065521.md) | 2026-06-30 | $10.4m | 6,090,301 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.9m | 4,669,585 | | Added +777,692 | | [MIC Capital Management UK LLP](/funds/1889830.md) | 2026-06-30 | $7.6m | 4,460,700 | | Unchanged | | [TUDOR INVESTMENT CORP ET AL](/funds/923093.md) | 2026-06-30 | $6.5m | 3,835,200 | Call | Added +3,280,000 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $5.9m | 3,498,869 | | Added +211 | | [WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST](/funds/1026720.md) | 2026-06-30 | $5.6m | 3,309,123 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.4m | 2,607,289 | | Added +1,520,424 | | [ICONIQ Capital, LLC](/funds/1569709.md) | 2026-06-30 | $4.4m | 2,559,090 | | Unchanged | ## Recent filings [All 252 filings](/companies/nmra/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 07:23 ET | [10-Q](/filings/0001193125-26-350370.md) | Quarterly report, period 2026-06-30 | 0001193125-26-350370 | | 2026-08-14 | 07:13 ET | [8-K](/filings/0001193125-26-350349.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-350349 | | 2026-07-27 | 07:07 ET | [8-K](/filings/0001193125-26-316819.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-316819 | | 2026-06-15 | 08:15 ET | [8-K](/filings/0001193125-26-270328.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-270328 | | 2026-05-29 | 16:05 ET | [8-K](/filings/0001193125-26-248244.md) | 5.07 Shareholder vote results | 0001193125-26-248244 | | 2026-05-07 | 16:01 ET | [10-Q](/filings/0001193125-26-211825.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211825 | | 2026-05-07 | 07:10 ET | [8-K](/filings/0001193125-26-210310.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210310 | | 2026-04-17 | 16:04 ET | [DEF 14A](/filings/0001193125-26-161489.md) | Proxy statement, period 2026-05-27 | 0001193125-26-161489 | | 2026-04-01 | 16:10 ET | [SCHEDULE 13D/A](/filings/0001012975-26-000294.md) | Ownership report, active investor, amended | 0001012975-26-000294 | | 2026-03-30 | 07:07 ET | [10-K](/filings/0001193125-26-130388.md) | Annual report, period 2025-12-31 | 0001193125-26-130388 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-130388.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1885522 - Tickers: NMRA - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.